The ADMC is one of six consortia funded by the National Institute of Aging’s large initiative:
AMP-AD Target Discovery and Preclinical Validation Project
The central goal of the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) Target Discovery and Preclinical Validation Project is to shorten the time between the discovery of potential drug targets and the development of new drugs for Alzheimer’s disease treatment and prevention, by integrating the analyses of large-scale molecular data from human brain samples with network modeling approaches and experimental validation.
The project is a consortium of six multi-institutional, multidisciplinary cooperative agreement grants. The grant awardees are applying cutting-edge systems and network biology approaches to integrate multidimensional human “omic” data (genomic, epigenomic, RNAseq, proteomic) from more than 2,000 human brains at all stages of the disease with clinical and pathological data to:
- discover novel therapeutic targets for Alzheimer’s disease
- gain a systems-level understanding of the gene, protein, and metabolic networks within which these novel targets operate
- evaluate their drugability in multiple model organisms